Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

(Reuters) - Johnson & Johnson (NYSE: JNJ) sued Samsung (KS: 005930) Bioepis for allegedly breaching a contract agreement over ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Lowering the price of the 2.5 mg dose vial to $349 per month. Lowering the price of the 5 mg dose vial to $499 per month.

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...